Movement Disorder News and Research RSS Feed - Movement Disorder News and Research

Movement disorders are neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness, paralysis of spasticity of the muscles. They affect the speed, fluency or smoothness, quality, and ease of movement.

Study reveals factors that contribute to eye mobility disorder

Imagine you cannot move your eyes up, and you cannot lift your upper eyelid. You walk through life with your head tilted upward so that your eyes look straight when they are rolled down in the eye socket. [More]
Impax resubmits NDA for RYTARY providing updated safety and stability information

Impax resubmits NDA for RYTARY providing updated safety and stability information

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA). [More]
Scientists work together to get a better understanding of Parkinson's disease

Scientists work together to get a better understanding of Parkinson's disease

Each day, 80 people are newly diagnosed with Parkinson's disease (PD) in the UK and one in 20 will be under the age of 40. [More]
GLNT receives allowance of patent for Parkinson's disease monitoring technology

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment. [More]

Researchers identify high levels of certain protein in brains of people suffering from essential tremor

A team of researchers from Universit- Laval and CHU de Qu-bec identified unusually high levels of a certain protein in the brains of people suffering from essential tremor (ET), a movement disorder that affects 4% of the adult population. [More]
Researchers develop new handheld electronic device that help overcome hand shakes caused by tremor

Researchers develop new handheld electronic device that help overcome hand shakes caused by tremor

​For people whose hands shake uncontrollably due to a medical condition, just eating can be a frustrating and embarrassing ordeal - enough to keep them from sharing a meal with others. [More]
New study may open door to better diagnosis, treatment for chronic insomnia

New study may open door to better diagnosis, treatment for chronic insomnia

Johns Hopkins researchers report that people with chronic insomnia show more plasticity and activity than good sleepers in the part of the brain that controls movement. [More]
Novel compound appears to protect mice against movement problems associated with PD

Novel compound appears to protect mice against movement problems associated with PD

Scientists report that they have developed a novel compound that appears to protect mice against developing movement problems associated with Parkinson's disease (PD). The research, which could one day in the future translate into a therapy that could halt the progression of PD and thereby prevent the symptoms of the disease, appears in ACS' Journal of Medicinal Chemistry. [More]
Researchers find link between mutations in gene called RAB 24 and inherited neurodegenerative disease

Researchers find link between mutations in gene called RAB 24 and inherited neurodegenerative disease

Researchers from North Carolina State University have found a link between a mutation in a gene called RAB 24 and an inherited neurodegenerative disease in Old English sheepdogs and Gordon setters. The findings may help further understanding of neurodegenerative diseases and identify new treatments for both canine and human sufferers. [More]

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received another allowance of claims from the U.S. Patent Office. The application covers a system and method of controlling Parkinson's therapy in response to motor symptoms. [More]
NIH data-sharing may advance genetic and translational research, therapeutic target discovery

NIH data-sharing may advance genetic and translational research, therapeutic target discovery

For the first time, large-scale information on the biochemical makeup of small interfering RNA (siRNA) molecules is available publicly. These molecules are used in research to help scientists better understand how genes function in disease. [More]
Exercise program improves symptoms of depression in patients with Parkinson's disease

Exercise program improves symptoms of depression in patients with Parkinson's disease

A new study by a movement disorder neurologist at The Ohio State University Wexner Medical Center found that depression improved among patients with Parkinson's disease who participated in a long-term group exercise program. [More]

VISIUS iMRI and ClearPoint guidance platform make DBS surgery an option for children with dystonia

IMRIS Inc. and MRI Interventions, Inc. today announced that Cook Children's Medical Center in Fort Worth, Texas, is the first U.S. pediatric hospital to offer asleep deep brain stimulation surgery to children suffering from dystonia by utilizing the combination of MRI Interventions' ClearPoint Neuro Intervention System and an IMRIS VISIUS Surgical Theatre for real-time intraoperative image guidance and procedure visualization. [More]

Henry Ford offers electric stimulation of brain using FDA-approved device for hard-to-treat epilepsy cases

Because of its participation in a pivotal trial, Henry Ford Hospital will be the first in Michigan to offer electric stimulation of the brain using a newly FDA-approved device for hard-to-treat epilepsy cases. [More]

Boston Scientific gets CE Mark approval for Vercise Deep Brain Stimulation System

The Boston Scientific Corporation Vercise Deep Brain Stimulation System has received CE Mark approval for the treatment of intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions. [More]
InSightec: First patient treated in ExAblate Neuro Phase III pivotal trial for tremor

InSightec: First patient treated in ExAblate Neuro Phase III pivotal trial for tremor

InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients. [More]

GLNT integrates video conferencing technology into Kinesia HomeView for Parkinson’s disease patients

Great Lakes NeuroTechnologies announced today they are launching commercialization and clinical studies to expand their telemedicine technology, Kinesia HomeView, for individuals with Parkinson’s disease by adding real-time video conferencing. [More]
Parkin protein plays key role in destruction of bacteria that cause tuberculosis

Parkin protein plays key role in destruction of bacteria that cause tuberculosis

A protein at the center of Parkinson's disease research now also has been found to play a key role in causing the destruction of bacteria that cause tuberculosis, according to scientists led by UC San Francisco microbiologist and tuberculosis expert Jeffery Cox, PhD. [More]

Scientists identify new drugs that have potential to slow down progression of Parkinson's

New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind. [More]
Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006. [More]